IBC-Ab002
Early Alzheimer's disease
Phase 1Active
Key Facts
About ImmunoBrain Checkpoint
Israeli biotech harnessing peripheral immune modulation to treat Alzheimer’s disease with an anti‑PD‑L1 antibody.
View full company profileTherapeutic Areas
Other Early Alzheimer's disease Drugs
| Drug | Company | Phase |
|---|---|---|
| AD04™ | ADvantage Therapeutics | Phase 2 |
| Lecanemab (Leqembi®) | BioArctic AB | Approved |
| AL101 / GSK4527226 | Alector | Phase 2 |
| AL002 | Alector | Phase 2 |
| Sabirnetug (ACU193) - Intravenous (IV) | Acumen Pharmaceuticals | Phase 2 |
| Sabirnetug (ACU193) - Subcutaneous (SC) | Acumen Pharmaceuticals | Phase 1 |